Boundless Bio Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
82
- Stock Symbol
-
BOLD
- Share Price
-
$9.67
- (As of Friday Closing)
Boundless Bio General Information
Description
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.
Contact Information
Corporate Office
- 9880 Campus Point Drive
- Suite 120
- San Diego, CA 92121
- United States
Boundless Bio Timeline
Boundless Bio Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.67 | $9.96 | $8.51 - $15.24 | $215M | 22.3M | 201K | -$14.96 |
Boundless Bio Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 445,970 | |||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (58,470) | (53,759) | (45,627) | (24,624) |
| Net Income | (53,145) | (49,434) | (45,901) | (25,210) |
| Total Assets | 117,077 | 129,894 | 76,829 | 113,719 |
| Total Debt | 1,523 | 2,195 | 5,183 | 377 |
Boundless Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Boundless Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Boundless Bio Comparisons
Industry
Financing
Details
000000
0000 0
Boundless Bio Competitors (29)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| NexImmune | Formerly VC-backed | Gaithersburg, MD | 00 | 00000 | 00000000 | 00000 |
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | 0000 | 00000 | 000000&0 | 00000 |
| Intensity Therapeutics | Formerly PE-Backed | Westport, CT | 00 | 0000 | 00000000 | 0000 |
| Senti Bio | Formerly VC-backed | South San Francisco, CA | 00 | 00000 | 000000000000 | 00000 |
| Adimab | Venture Capital-Backed | Lebanon, NH | 000 | 00000 | 0000000000 0 | 00000 |
Boundless Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Boundless Bio Patents
Boundless Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20230272485-A1 | Replication stress pathway agent compositions and methods for treating cancer | Pending | 16-Feb-2022 | 0000000000 | |
| CA-3231660-A1 | Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof | Pending | 17-Sep-2021 | 0000000000 | |
| AU-2022345092-A1 | Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof | Pending | 17-Sep-2021 | 0000000000 | |
| US-20230026313-A1 | Checkpoint kinase 1 (chk1) inhibitors and uses thereof | Active | 27-May-2021 | 0000000000 | |
| US-11707462-B2 | Checkpoint kinase 1 (chk1) inhibitors and uses thereof | Active | 27-May-2021 | A61K31/497 | 00 |
Boundless Bio Executive Team (9)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Zachary Hornby | Chief Executive Officer & Board Member | ||
| Jami Rubin | Chief Financial Officer, Finance | ||
| Jessica Oien JD | Secretary, Administration & Chief Legal Officer, Legal | ||
| David Hinkle | Senior Vice President of Finance & Controller | ||
| Christian Hassig Ph.D | Executive |
Boundless Bio Board Members (13)
| Name | Representing | Role | Since |
|---|---|---|---|
| Benjamin Cravatt Ph.D | Self | Co-Founder, Scientific and Clinical Advisor & Board Member | 000 0000 |
| Christine Brennan Ph.D | Vertex Ventures HC | Board Member | 000 0000 |
| Fabio Pucci Ph.D | RA Capital Management | Board Member | 000 0000 |
| Ho Cho Ph.D | Boundless Bio | Board Member | 000 0000 |
| Jakob Loven Ph.D | Nextech Invest | Board Member | 000 0000 |
Boundless Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Boundless Bio FAQs
-
When was Boundless Bio founded?
Boundless Bio was founded in 2018.
-
Who is the CEO of Boundless Bio?
Zachary Hornby is the CEO of Boundless Bio.
-
Where is Boundless Bio headquartered?
Boundless Bio is headquartered in San Diego, CA.
-
What is the size of Boundless Bio?
Boundless Bio has 82 total employees.
-
What industry is Boundless Bio in?
Boundless Bio’s primary industry is Drug Discovery.
-
Is Boundless Bio a private or public company?
Boundless Bio is a Public company.
-
What is Boundless Bio’s stock symbol?
The ticker symbol for Boundless Bio is BOLD.
-
What is the current stock price of Boundless Bio?
As of 17-May-2024 the stock price of Boundless Bio is $9.67.
-
What is the current market cap of Boundless Bio?
The current market capitalization of Boundless Bio is $215M.
-
Who are Boundless Bio’s competitors?
NexImmune, Kite Pharma, Intensity Therapeutics, Senti Bio, and Adimab are some of the 29 competitors of Boundless Bio.
-
What is Boundless Bio’s annual earnings per share (EPS)?
Boundless Bio’s EPS for 12 months was -$14.96.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
